Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

COX-2 Review Highlights “Conundrum” Of FDA Drug Safety Regulation

Executive Summary

FDA's summary of the COX-2 inhibitor safety review underscores the "conundrum" posed by drug safety regulation

You may also be interested in...



Vioxx Route To Re-Approval Outlined By FDA As Merck Mulls Options

Conflicting opinions from FDA advisory committee members on the safety of Vioxx necessitates additional committee consideration prior to re-approval of the COX-2 inhibitor, an FDA memo states

Vioxx Route To Re-Approval Outlined By FDA As Merck Mulls Options

Conflicting opinions from FDA advisory committee members on the safety of Vioxx necessitates additional committee consideration prior to re-approval of the COX-2 inhibitor, an FDA memo states

Bextra Withdrawn At FDA’s Request; Pfizer Holds Out Hope For Return

Pfizer will have to show a "unique" benefit associated with Bextra in order to justify a return to the U.S. market, FDA Office of New Drugs Director John Jenkins said during an April 7 media conference call announcing the withdrawal of the COX-2 inhibitor

Topics

UsernamePublicRestriction

Register

LL009864

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel